

• (P) 973.925.7200

• BarnertPharmacy.com

• (F) 973.925.7202

**Patient Information**

Patient Name \_\_\_\_\_ Today's Date \_\_\_\_\_  NEW Patient  CURRENT Patient  
 DOB \_\_\_\_\_ Height \_\_\_\_\_ Weight \_\_\_\_\_  Male  Female Preferred Language \_\_\_\_\_  
 Best Phone \_\_\_\_\_ Email \_\_\_\_\_  
 Street Address \_\_\_\_\_ Apt# \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Ship to Patient at:  Home  Physician Office  Work Address  
 Allergies \_\_\_\_\_  
 Current Medications including OTC's (please fax a complete list) \_\_\_\_\_

**Please Fax Insurance Card(s) both sides**

Insured's Name \_\_\_\_\_  
 Relation to Patient \_\_\_\_\_  
 Primary Insurance \_\_\_\_\_  
 ID# \_\_\_\_\_ Group# \_\_\_\_\_  
 Secondary Insurance \_\_\_\_\_  
 ID# \_\_\_\_\_ Group# \_\_\_\_\_

**Ordering Prescriber**

Office Contact \_\_\_\_\_  
 Street Address \_\_\_\_\_ Suite # \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Tel \_\_\_\_\_ Fax \_\_\_\_\_  
 Email \_\_\_\_\_  
 License# \_\_\_\_\_  
 NPI# \_\_\_\_\_

- |  |  |
|--|--|
| <p><b>ICD-10 Code</b> <input type="checkbox"/> <b>C90.0</b> Multiple Myeloma<br/> <input type="checkbox"/> <b>C91.10</b> Lymphoid Leukemia<br/> <input type="checkbox"/> <b>D80.0</b> Hereditary Hypogammaglobulinemia<br/> <input type="checkbox"/> <b>D80.2</b> Selective deficiency of IgA<br/> <input type="checkbox"/> <b>D80.5</b> Immunodeficiency with Increased IgM<br/> <input type="checkbox"/> <b>D81.2</b> SCID with Low or Normal B-Cell Numbers<br/> <input type="checkbox"/> <b>D81.9</b> Combined Immunodeficiency, Unspecified<br/> <input type="checkbox"/> <b>D83.8</b> Other Common Var. Immunodeficiencies<br/> <input type="checkbox"/> <b>E13.40</b> Other specified diabetes mellitus w/ diabetic neuropathy, unspecified<br/> <input type="checkbox"/> <b>G25.82</b> Stiff Person Syndrome<br/> <input type="checkbox"/> <b>G61.0</b> Guillain-Barre Syndrome (GBS)<br/> <input type="checkbox"/> <b>G62.9</b> Other Peripheral Neuropathy<br/> <input type="checkbox"/> <b>G70.0</b> Myasthenia Gravis (MG)<br/> <input type="checkbox"/> <b>G70.80</b> Lambert-Eaton Syndrome, unspecified<br/> <input type="checkbox"/> <b>L10.9</b> Pemphigus<br/> <input type="checkbox"/> <b>M32.9</b> Systemic lupus erythematosus (SLE)<br/> <input type="checkbox"/> <b>M33.90</b> Dermatopolymyositis &amp; Organ Involvement Unspecified<br/> <input type="checkbox"/> <b>Q81.9</b> Epidermolysis Bullosa<br/> <input type="checkbox"/> <b>Z94.81</b> BMT</p> | <p><input type="checkbox"/> <b>C90.1</b> Plasma Cell Leukemia<br/> <input type="checkbox"/> <b>D69.6</b> Thrombocytopenia<br/> <input type="checkbox"/> <b>D80.1</b> Nonfamilial Hypogammaglobulinemia<br/> <input type="checkbox"/> <b>D80.3</b> Selective deficiency of IgG Subclasses<br/> <input type="checkbox"/> <b>D81.1</b> SCID with Low T- and B- Cell Numbers<br/> <input type="checkbox"/> <b>D81.89</b> Other combined Immunodeficiencies<br/> <input type="checkbox"/> <b>D83.1</b> CVID w/ Predominant Immunoregulatory T-Cell Disorders<br/> <input type="checkbox"/> <b>D83.9</b> Common Var. Immunodeficiency, Unspecified<br/> <input type="checkbox"/> <b>D84.9</b> CVID<br/> <input type="checkbox"/> <b>G35</b> Multiple Sclerosis (MS)<br/> <input type="checkbox"/> <b>G61.81</b> Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)<br/> <input type="checkbox"/> <b>G63</b> Polyneuropathy in diseases classified elsewhere<br/> <input type="checkbox"/> <b>G70.01</b> Myasthenia Gravis with (Acute) Exacerbation<br/> <input type="checkbox"/> <b>L12.0</b> Pemphigoid<br/> <input type="checkbox"/> <b>M30.3</b> Kawasaki's syndrome<br/> <input type="checkbox"/> <b>M33.20</b> Polymyositis, Organ Involvement Unspecified<br/> <input type="checkbox"/> <b>M36.0</b> Dermatomyositis<br/> <input type="checkbox"/> <b>Z41.8</b> Prophylactic Immunotherapy<br/> <input type="checkbox"/> <b>Other</b> _____</p> |
|--|--|

**Prescription**

**SUPPLIES FOR INFUSION** (If Necessary)  
 NaCl 0.9% / D5W for flush: flush Line/Port with (3 - 5 ml for PIV and 5-10 ml for Central Line/Port) per nursing agency protocol (NaCl 0.9% / D5W will be used based on IVIG compatibility)  
 Heparin for flush (100 Units / ml) (if RN keeps PIVor if needed for Central Line), flush with 3-5 ml per nursing agency protocol  
 Sterile water for reconstitution of powder to make the requested concentration (for Carimune NF)  
 Other: \_\_\_\_\_

**PRE-MEDICATIONS:** To be administered 30 min prior to IVIG Infusion: (QTY: per infusion):  Acetaminophen 650 mg PO  
 Diphenhydramine 25 mg-50 mg  Other: \_\_\_\_\_

**IVIG (IMMUNOGLOBIN) ORDER:** \_\_\_\_\_ (IVIG brand will be chosen if not specified)

**INTRAVENOUS IMMUNOGLOBULIN** Dose  0.4 gm/kg  1gm/kg  2gm/kg  gm  
 Infuse:  IV daily for \_\_\_\_\_ day(s); repeat every \_\_\_\_\_ week(s) for \_\_\_\_\_ cycles Refills: \_\_\_\_\_  
 Other \_\_\_\_\_ Refills: \_\_\_\_\_

**SUBCUTANEOUS IMMUNOGLOBULIN** Infuse:  gm OR \_\_\_\_\_ ml using \_\_\_\_\_ sites \_\_\_\_\_ time(s) per week for \_\_\_\_\_  
 Hydration order:  \_\_\_\_\_ ml NS IV to be infused prior/concurrently with IVIG Refills: \_\_\_\_\_

ACCESS	NS HEPARIN	100 u/ml (If applicable, flush IV access device per Pharmacy protocol)
Peripheral	1-3ml before/after use	10u/ml 1-2mls after last NS flush
Midline, central (non-port), PICC	NS 5-10 mls before/after use;	10mls after blood draw 10 u/ml 3-5mls after last NS flush; 5mls after blood draw
Implanted Port	5-10mls before/after use;	20mls after blood draw 100 u/ml 5mls after last NS flush; 5mls after blood draw
Tunneled	5-10mls before/after use;	20mls after blood draw 10 u/ml 3- mls after last NS flush. 5mls after blood draw
Groshong PICC, Midline	5-10mls before/after use;	10mls after blood draw NO Heparin needed

**IN THE EVENT OF ANAPHYLAXIS:**  
 • Stop Infusion and call MD & 911  
 • Diphenhydramine 25 - 50 mg IVP every 4 hours prn (Not to exceed 25 mg/min) QTY: 3 (50 mg)  
 • Epinephrine (1:1000) 0.4 mg SQ prn anaphylaxis, may repeat every 20 minutes x 2 QTY: 3 amp  
 Other \_\_\_\_\_

**ENROLL IN NURSE TRAINING / MANUFACTURER PROGRAM**

By signing this form I authorize Barnert Pharmacy and its representatives to act as my agent in order to initiate and execute the insurance prior authorization process and, in doing so release clinical information via phone to the appropriate third party payer.

\_\_\_\_\_  
**Prescriber's signature** (no stamps) if brand required check this  DAW \_\_\_\_\_ **Date** \_\_\_\_\_